Welcome to our dedicated page for NutriBand SEC filings (Ticker: NTRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutriband Inc. filings document material events for a Nevada public company developing prescription transdermal pharmaceutical products. Recent Form 8-K disclosures cover Regulation FD press releases related to the company’s abuse-deterrent fentanyl transdermal system and brand-name development, as well as board actions involving an operating subsidiary agreement.
The filing record also describes the company’s Nasdaq-listed common stock and warrants, annual meeting voting matters, director elections, auditor ratification, amendments to organizational documents, governance procedures, and other capital-structure and shareholder matters reported through current reports.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported modest revenue growth but significantly higher losses for the quarter and nine months ended October 31, 2025. Revenue for the quarter fell to $346,058 from $645,796, while nine‑month revenue rose to $1.64M from $1.50M, all from its Pocono Pharmaceuticals manufacturing segment.
Despite a nine‑month gross profit of $477,367, heavy selling, general and administrative costs of $6.07M and research and development spending of $1.70M on the AVERSA Fentanyl program drove a nine‑month net loss of $7.26M. A non‑cash preferred stock dividend valued at $21.81M pushed the net loss available to common stockholders to $29.08M, or ($2.54) per share.
Nutriband ended the period with cash of $5.31M and working capital of $5.04M, supported by prior equity financing and warrant exercises. Management’s forecasts lead them to conclude that earlier substantial doubt about continuing as a going concern is alleviated. The company continues development of its AVERSA abuse‑deterrent transdermal products with partner Kindeva and has outstanding warrants and stock options that could further affect its capital structure.
NutriBand Inc. (NTRB) CEO and director Gareth Sheridan, who is also a 10% owner, reported his annual holdings for the fiscal year ended 01/31/2025. He beneficially owned 1,761,667 shares of NutriBand common stock in direct ownership at year-end.
Sheridan also reported stock options as derivative securities. On 03/20/2024, he received stock options for 97,500 shares with a $2.61 exercise price, expiring on 03/20/2027. On 01/29/2025, he received additional stock options for 29,333 shares with a $8.07 exercise price, expiring on 01/29/2028. Following these transactions, he held 251,000 stock options in total, all reported as directly owned.
Nutriband Inc. filed a current report on Form 8-K to furnish information under Item 7.01, Regulation FD Disclosure. The company refers readers to an attached press release dated October 28, 2025, filed as Exhibit 99.1.
Nutriband’s common stock (symbol NTRB) and warrants (symbol NTRBW) are listed on The Nasdaq Stock Market LLC. The report is signed on behalf of Nutriband Inc. by Chief Executive Officer Gareth Sheridan.
NutriBand (NTRB) CFO Gerald Goodman filed a Form 5 for the fiscal year ended 01/31/2025, reporting year-end holdings and prior transactions under Section 16. The filing shows 66,085 shares of common stock beneficially owned at fiscal year-end, held directly.
Reported transactions include: acquisition of 60,085 common shares at $1.93 on 10/27/2023; a warrant at $1.93 tied to 60,085 underlying shares with an expiration date of 10/27/2026; a stock option grant for 75,000 shares at $1.93 on 03/19/2024 expiring 03/19/2027; and a stock option grant for 17,667 shares at $7.34 on 01/23/2025 expiring 01/23/2028. Ownership is indicated as direct for the securities listed.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.